Matthew Frank, MD, PhD, on Eliciting Response in Pretreated LBCL With CD22-Targeted CAR T Cells
A presentation at EHA 2023 showed important safety and efficacy data with CD22 CAR T cells in heavily pretreated patients with large B-cell lymphoma and pointed to how this may shed light on sequencing in this field.
Assessing GPRC5D-Targeted CAR T Therapy for R/R Multiple Myeloma
Susan Bal, MD, assistant professor of medicine at University of Alabama – Birmingham, discussed new data on BMS-986393.
Nikhil Munshi, MD, on Final Data on Cilta-Cel in Multiple Myeloma From CARTITUDE-1
The associate professor from Dana Farber Cancer Center and Harvard Medical School discussed continued efficacy and safety data presented at the 2023 EHA Meeting.
Susan Bal, MD, on Promising Efficacy With GPRC5D-CAR Therapy in R/R Multiple Myeloma
The assistant professor of medicine at University of Alabama – Birmingham discussed efficacy findings on BMS-986983 and more research to be done.
Mustang Bio’s CAR-T MB-106 Achieves Responses in Waldenstrom Macroglobulinemia, Follicular Lymphoma
Two of 6 patients in the WM cohort achieved a complete response and 16 of 20 patients in the FL cohort achieved a complete response.
Matthew Frank, MD, PhD, on Tackling Antigen Loss and Absence in Hematological Malignancies
The assistant professor of medicine in the Division of Blood and Marrow Transplantation and Cellular Therapy at Stanford University discussed potential methods for optimizing CAR-T efficacy that could be explored in the future.
Susan Bal, MD, on Favorable Safety of BMS-986393 in R/R Multiple Myeloma
The assistant professor of medicine at University of Alabama – Birmingham discussed new data from the first-in-human trial of the CAR T-cell therapy.
Matthew Frank, MD, PhD, on Evaluating CD22-directed CAR-T CAR22 in R/R B-cell Malignancies
The assistant professor of medicine in the Division of Blood and Marrow Transplantation and Cellular Therapy at Stanford University discussed the safety and efficacy results he presented at EHA’s 2023 congress.
CAR-T WU-CART-007 Shows Evidence of Antileukemic Activity Among Patients With T-ALL/LBL
The objective response rate among patients treated at DL2 and DL3 who were evaluable for efficacy was 57%.
Nausheen Ahmed, MD, on the Impact of Prior Treatments on the Safety of Brexu-cel
The assistant professor in the Division of Hematologic Malignancies and Cellular Therapeutics at the University of Kansas Medical Center discussed real-world safety outcomes for brexu-cel in patients with r/r MCL.
EDIT-301 Increases Total and Fetal Hemoglobin in Patents with Sickle Cell Disease
The therapy seems to have a similar benefit in the first patient with TDT in the EdiTHAL trial.
Lentiviral Gene Therapy Stabilizes Patients With MPS1H
Follow-up data up to 3 years showed supraphysiologic levels of blood IDUA and decrease of GAGs.
Nausheen Ahmed, MD, on Real-world Efficacy Data for Brexu-cel in Patients With R/R Mantle Cell Lymphoma
The assistant professor in the Division of Hematologic Malignancies and Cellular Therapeutics at the University of Kansas Medical Center discussed the real-world data she is presenting at EHA’s 2023 congress.
Mazyar Shadman, MD, MPH, on MB-106's Potential in Follicular Lymphoma
The associate professor at Fred Hutch Cancer Center discussed data presented at the EHA 2022 Congress.
T-Charge CAR T-Cell Therapy Shows Efficacy in Multiple Myeloma
The therapy is now being evaluated in a phase 2 study.
CTX130 Shows Acceptable Safety Profile, Clinically Meaningful Responses in R/R T-Cell Lymphoma
CTX130 is also being investigated for the treatment of r/r renal cell carcinoma in a phase 1 clinical trial called COBALT-RCC (NCT04438083).
CAR T-Cell Therapy Yields High Response Rates in Follicular Lymphoma
Mustang Bio presented data on MB-106 at the 2022 EHA Congress.
Tisa-Cel Shows Durable Efficacy in Pediatric and Young Adult Patients With R/R B-Cell Acute Lymphoblastic Leukemia
Among treated patients, 42% achieved 5-year event free survival.
Dual-Targeted CAR T-Cell Therapy Continues to Show Efficacy in R/R Multiple Myeloma
GC012F also showed efficacy in B-cell non-Hodgkin lymphoma.
Anbal-Cel Shows Promising Responses in Large B-Cell Lymphoma
The CD-19 CAR T-cell therapy is developed using Curocell’s OVISTM platform.
Exa-Cel Eliminates Transfusions in TD Thalassemia and VOCs in Sickle Cell Disease
Results from the CLIMB THAL-111 and CLIMB SCD-121 trials were presented at the EHA 2022 Congress.
Axi-Cel More Efficacious With Higher Toxicity Than Tisa-Cel in Diffuse Large B-Cell Lymphoma
Response rates were significantly higher but patients had more cases of ICANS and CRS with axi-cel treatment compared to tisa-cel treatment.
Lentiviral CAR T Therapy Delivers Good Efficacy, Safety in R/R Multiple Myeloma
Participants in the trial achieved a sustained response and experienced low-grade toxicity.
CD30-Targeted CAR T Cell Therapy Promising in Heavily Pretreated Hodgkin Lymphoma
A phase 2 clinical trial evaluating a T-cell memory enriched anti-CD30 CAR-T is now underway.
CD33 CAR NK Cell Therapy Shows Improved Targeting in Acute Myeloid Leukemia
As of the data cutoff, 3 of 5 treated participants remain in complete response.
Ide-Cel Treatment Associated With Greater Quality of Life Than Belantamab Mafodotin in R/R MM
Statistically significant differences were seen in global health status, pain, and fatigue.
Allogeneic CAR T-Cell Therapy Yields 100% CR Rate in B-NHL
Three of 6 patients have an ongoing response.
Using A Modular Approach to Develop Oncolytic Cell Therapies
The chief executive and chief medical officers of Celyad Oncology discussed their platform and positive data presented at EHA 2021.
CD20-Targeted Gene Therapy
Manuel Litchman, MD, the president, chief executive officer, and director of Mustang Bio discussed the company’s lead and second program.
Investigating CAR T in Lymphoma, Leukemia, and Solid Tumors
The president, chief executive officer, and director of Mustang Bio discussed the company’s pipeline.
2 Clarke Drive Cranbury, NJ 08512